Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04840914 Completed - Clinical trials for Chronic Heart Failure With Reduced Ejection Fraction

A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.

NCT ID: NCT04840043 Completed - Clinical trials for Osteopathic Manipulative Treatment

Osteopathic Sympathetic Harmonization and Depression

Start date: October 11, 2017
Phase: N/A
Study type: Interventional

Depression appears to be resistant to the available pharmacological treatments. Autonomic responses accompanied by any psychological stress are sympathetic nervous system (SNS) and neuroendocrine responses are formed by hypothalamus-pituitary-adrenal (HPA) axis. The purpose of this study is; assessment of effectiveness of osteopathic approach on sympathetic nervous system and HPA axis in adolescents with depression.

NCT ID: NCT04839822 Completed - Clinical trials for Depressive; Episode, Major

Efficacy of Edupression.Com® in Depressive Patients

eFICASY
Start date: April 28, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the efficacy and adherence of the digital self-help programme edupression.com®.

NCT ID: NCT04839562 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Start date: August 6, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.

NCT ID: NCT04839146 Completed - Covid19 Clinical Trials

Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)

COUGH-1
Start date: March 11, 2021
Phase: Phase 1
Study type: Interventional

This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the immunogenicity-tolerability ratio 14 days following first vaccination with ABNCoV2.

NCT ID: NCT04838977 Completed - Clinical trials for Post-Traumatic Stress Disorder in Children

Recovery After Stress Toolkit (RESET) Study

ReSeT
Start date: July 23, 2021
Phase: N/A
Study type: Interventional

This study evaluates the use of web-based educational modules combined with telehealth delivered therapy for children with post-traumatic stress symptoms (PTSS) after receiving hospital based medical attention for an injury. Half of the participants will received the online therapy and half of the participants will receive usual care.

NCT ID: NCT04838795 Completed - Clinical trials for SARS (Severe Acute Respiratory Syndrome)

Sisonke (Together): OPEN LABEL TRIAL COVID-19

Sisonke
Start date: February 17, 2021
Phase: Phase 3
Study type: Interventional

To monitor the effectiveness of the single-dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) in South Africa

NCT ID: NCT04838067 Completed - Clinical trials for Sleep Initiation and Maintenance Disorders

Validation of Therapeutic Effects of Cefaly on Insomnia

Start date: July 26, 2018
Phase: N/A
Study type: Interventional

The study aims to examine whether the Cefaly has a therapeutic effect on insomnia patients visiting a psychiatric clinic in Korea. The study design is a single site, single-armed exploratory study. Insomnia patients received a 20-minute daily sessions of the Cefaly for 4 weeks. Primary endpoint was a reduction of scores in Pittsburgh Sleep Quality Index, Insomnia Severity Index, Epworth Sleepiness Scale, improvements in polysomnography measures, and changes in resting state networks, cortical thickness, fractional anisotropy and mean diffusivity

NCT ID: NCT04837963 Completed - Clinical trials for Hirschsprung Disease

Does Hirschsprung Disease Increase the Risk of Febrile Urinary Tract Infection in Children

Start date: May 16, 2021
Phase:
Study type: Observational

Febrile urinary tract infection (FUTIs) are the most common bacterial infections in children under the age of 2 years. They represent 7% of children presenting with fever without a source. In case of recurrent or undertreated FUTIs there is a risk for kidney function with the threat of chronic renal failure [7]. They are more often isolated but some FUTIs may reveal an underlying and facilitating condition. Beside the well-known congenital anomalies of the kidneys and urinary tract such as reflux or obstructions, others risk factors for FUTI are reported. Age less than 1 year, uncircumcised males, poor fluid intake, bladder bowel dysfunction (BBD) including dysfunctional voiding pattern and constipation increase the risk of FUTI. The prevalence of BBD in children with FUTIs is far higher than in the general population. Recommendations emphasize on an efficient treatment of BBD in the first-line management of recurring FUTIs and it has been proven to be efficient (ref). One of the BBD may include Hirschsprung's Disease (HD). HD is the first congenital malformation of the enteric nervous system with a reported prevalence of 1 in 5000 live birth. It's characterized by an aganglionosis and subsequent dysmotility affect by always the anal canal, most commonly there is a rectosigmoid form (74-80%), and less commonly involves a long segment of colon (12-22%) or a total colonic aganglionosis with ileal involvement upto 50 cm proximal to ileocecal junction (4-13%). The treatment is based on the resection of dysfunctional segment of colon with an anastomosis between the normally innervated bowel to the anus, while preserving normal sphincter function. But significant bowel dysfunction may persist postoperatively. 20% of the children present a fecal incontinence, and 14% a constipation in long-term studies. Bladder dysfunction and associated urological anomalies are also reported in these patients. All of that may facilitate the occurrence of febrile urinary tract infections (FUTI) in patients with HD. Unfortunately, few studies focused on this specific population. The objective of this study was to find out whether children with HD are more prone to develop FUTIs than controls and which patient with HD are more at risk to develop UTIs.

NCT ID: NCT04837651 Completed - Multiple Sclerosis Clinical Trials

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

OCR-VAX
Start date: March 2, 2021
Phase:
Study type: Observational

The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. B-cell mediated humoral responses and adaptive T-cell mediated cellular responses were measured in patients treated with OCR who received any of the available SARS-CoV-2 vaccines, 3-4 weeks after completion of vaccination.